サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1772195

がん遺伝子治療の市場規模、シェア、動向分析レポート：適応症別、ベクタータイプ別、投与経路別、地域別、セグメント別予測、2025年～2030年

Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Indication, By Vector Type, By Route Of Administration, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
がん遺伝子治療の市場規模、シェア、動向分析レポート：適応症別、ベクタータイプ別、投与経路別、地域別、セグメント別予測、2025年～2030年
出版日: 2025年06月26日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん遺伝子治療市場の成長と動向：

Grand View Research社の最新レポートによると、世界のがん遺伝子治療市場規模は2030年までに127億6,000万米ドルに達する見込みです。

同市場は、世界の新規治療薬に対する需要の増加と世界のがん罹患率の上昇により、2025年から2030年にかけてCAGR 19.34%を記録すると予測されています。さらに、この治療法はさまざまな種類の遺伝性がんや誘発性がんに対する絶対的な解決策を提供するため、がん治療薬としてより望ましい選択肢となっています。例えば、Kite社のTecartus（brexucabtagene autoleucel）は、再発または難治性のB細胞前駆体急性リンパ芽球性白血病の治療薬としてFDAに承認されています。

世界中で悪性腫瘍の有病率が増加しており、効果的な治療と悪性腫瘍の発生率の増加に対抗するための様々な戦略の必要性が推進されると予想されます。さらに、市場における技術の進歩は、新規治療薬に新たな機会を提供すると期待されています。その結果、製品の承認数が増加しています。例えば、2022年3月、欧州医療機関はCarvykti（ciltacabtagene autoleucel）を再発難治性多発性骨髄腫の治療に使用する条件付き販売承認を推奨しました。

同市場は、世界中の政府および各国がん学会からの有利な支援によって積極的に牽引されています。がん遺伝子治療の研究資金を増やすことにますます注目が集まっています。例えば、2021年12月、DARE-NL（オランダ）と呼ばれるオランダのプラットフォームは、KWFオランダがん協会から520万米ドルの助成金を獲得しました。この助成金により、DARE-NLは、恵まれない人々が利用できる細胞・遺伝子治療戦略をレベルアップすることができます。

アジアのメーカーは、大量生産が可能な複雑でない分子に重点を置いているため、新しく複雑な技術への投資は比較的少ないです。そのため、欧州や北米など他の先進地域のメーカーにとっては、競争圧力を回避するために、高収量・低コスト技術への投資が選択肢となっています。

市場で事業を展開する主な企業は、強力ながん遺伝子治療薬の開発のための共同研究に注力しています。例えば、2022年8月、Gensaic社はOvid Therapeutics社と、同社独自のファージ由来粒子遺伝子治療プラットフォームを用いた中枢神経系を適応症とする最大3種類の遺伝子医薬品の開発に関する共同研究契約を締結しました。

がん遺伝子治療市場レポートハイライト

  • 遺伝子レベルでのがん病態の解明が進み、遺伝子誘導免疫療法や個別化医療へのニーズが高まる中、市場は重要な変化を迎えています。
  • 遺伝子誘導免疫療法研究の進展により、遺伝子誘導免疫療法分野が2024年に最大シェアを占める。
  • 新規遺伝子治療に対する需要の高まりとがん遺伝子治療のFDA承認件数の増加により、バイオ製薬企業が2024年に最大の市場シェアを占めました。バイオ製薬企業は、この分野での研究開発活動の増加により、予測期間中に最も速い成長を示すと予測されています。
  • 北米は、主要企業の存在と、同地域におけるがん研究を推進するための政府および国立がん研究所からの支援増加により、2024年の市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助市場展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 業界分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 がん遺伝子治療市場：適応症ビジネス分析

  • 適応症セグメントダッシュボード
  • 世界のがん遺伝子治療市場の動向と変動分析
  • 世界のがん遺伝子治療市場規模と動向分析（適応症別、2018年～2030年）
  • 大細胞型B細胞リンパ腫
  • 多発性骨髄腫
  • 急性リンパ性白血病（ALL）
  • 黒色腫（病変）
  • その他

第5章 がん遺伝子治療市場：投与経路ビジネス分析

  • 投与経路セグメントダッシュボード
  • 世界のがん遺伝子治療市場における投与経路の変動分析
  • 世界のがん遺伝子治療市場規模と動向分析（投与経路別、2018年～2030年）
  • 静脈内
  • その他

第6章 がん遺伝子治療市場：ベクタータイプのビジネス分析

  • ベクタータイプセグメントダッシュボード
  • 世界のがん遺伝子治療市場におけるベクター型変動分析
  • 世界のがん遺伝子治療市場規模と動向分析（ベクタータイプ別、2018年～2030年）
  • レンチウイルス
  • レトロウイルスとガンマレトロウイルス
  • AAV
  • 改変単純ヘルペスウイルス
  • アデノウイルス
  • その他

第7章 がん遺伝子治療市場：適応症、投与経路、ベクタータイプ別の地域推定・動向分析

  • 地域ダッシュボード
  • 市場規模と予測および動向分析、2018年から2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • スイス
  • アジア太平洋
    • 日本
    • 中国
    • 韓国
  • 世界のその他の地域

第8章 競合情勢

  • 参入企業
  • 戦略マッピング
  • 企業市況分析、2024年
  • 参入企業の概要
    • Amgen Inc.
    • Novartis AG
    • Gilead Sciences, Inc.
    • bluebird bio, Inc.
    • Bristol-Myers Squibb Company
    • Legend Biotech.
    • Nanjing IASO Biotechnology
    • JW Therapeutics
    • CARsgen Therapeutics
    • Krystal Biotech, Inc.
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 4 Global cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 Global cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 6 Global cancer gene therapy market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America cancer gene therapy market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 9 North America cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 North America cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 11 U.S. cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 12 U.S. cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 13 U.S. cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 14 Canada cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 15 Canada cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 16 Canada cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 17 Mexico cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 18 Mexico cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Mexico cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 20 Europe cancer gene therapy market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 22 Europe cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Europe cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 24 UK cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 25 UK cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 26 UK cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 27 Germany cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 28 Germany cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 29 Germany cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 30 Switzerland cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 31 Switzerland cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32 Switzerland cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific cancer gene therapy market, by country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 37 Japan cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Japan cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Japan cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 40 China cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 41 China cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 42 China cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 43 South Korea cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 44 South Korea cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 45 South Korea cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 46 Rest of the world cancer gene therapy market, by indication, 2018 - 2030 (USD Million)
  • Table 47 Rest of the world cancer gene therapy market, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 Rest of the world cancer gene therapy market, by vector type, 2018 - 2030 (USD Million)
  • Table 49 Participant's overview
  • Table 50 Financial performance
  • Table 51 Key companies undergoing expansions
  • Table 52 Key companies undergoing acquisitions
  • Table 53 Key companies undergoing collaborations
  • Table 54 Key companies launching new products
  • Table 55 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Cancer gene therapy market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Market outlook
  • Fig. 8 Segment snapshot
  • Fig. 9 Competitive landscape snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Cancer gene therapy market driver analysis
  • Fig. 12 Cancer gene therapy market restraint analysis
  • Fig. 13 Cancer gene therapy market: Porter's analysis
  • Fig. 14 Cancer gene therapy market: PESTEL analysis
  • Fig. 15 Cancer gene therapy market: Indication outlook and key takeaways
  • Fig. 16 Cancer gene therapy market: Indication market share analysis, 2024 - 2030
  • Fig. 17 Global cancer gene therapy by large B-cell lymphoma market, 2018 - 2030 (USD Million)
  • Fig. 18 Global cancer gene therapy by multiple myeloma market, 2018 - 2030 (USD Million)
  • Fig. 19 Global cancer gene therapy by Acute Lymphoblastic Leukemia (ALL) market, 2018 - 2030 (USD Million)
  • Fig. 20 Global cancer gene therapy by melanoma (lesions) market, 2018 - 2030 (USD Million)
  • Fig. 21 Global cancer gene therapy by others market, 2018 - 2030 (USD Million)
  • Fig. 22 Cancer gene therapy market: Route of administration outlook and key takeaways
  • Fig. 23 Cancer gene therapy market: Route of administration market share analysis, 2024 - 2030
  • Fig. 24 Global cancer gene therapy by intravenous market, 2018 - 2030 (USD Million)
  • Fig. 25 Global cancer gene therapy by others market, 2018 - 2030 (USD Million)
  • Fig. 26 Cancer gene therapy market: Vector type outlook and key takeaways
  • Fig. 27 Cancer gene therapy market: Vector type market share analysis, 2024 - 2030
  • Fig. 28 Global cancer gene therapy by lentivirus market, 2018 - 2030 (USD Million)
  • Fig. 29 Global cancer gene therapy by retrovirus & gamma retrovirus market, 2018 - 2030 (USD Million)
  • Fig. 30 Global cancer gene therapy by AAV market, 2018 - 2030 (USD Million)
  • Fig. 31 Global cancer gene therapy by modified herpes simplex virus market, 2018 - 2030 (USD Million)
  • Fig. 32 Global cancer gene therapy by adenovirus market, 2018 - 2030 (USD Million)
  • Fig. 33 Global cancer gene therapy by others market, 2018 - 2030 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Canada cancer gene therapy market, 2018 - 2030 (USD Million)
  • Fig. 38 Mexico cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Europe cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 UK cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Germany cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Switzerland cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Asia-Pacific cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Japan cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 China cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Rest of the world cancer gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Key company categorization
  • Fig. 49 Company market positioning
  • Fig. 50 Market participant categorization
  • Fig. 51 Strategy framework
目次
Product Code: GVR-4-68039-984-2

Cancer Gene Therapy Market Growth & Trends:

The global cancer gene therapy market size is expected to reach USD 12.76 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 19.34% from 2025 to 2030 owing to the increasing demand for novel therapeutics globally and rising incidence of cancer cases globally. Moreover, this therapy offers an absolute solution to different kinds of inherited and induced cancer conditions, which makes it a more desired option for cancer therapeutics. For instance, Kite's Tecartus (brexucabtagene autoleucel) is approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

There is an increasing prevalence of malignant tumor cases across the globe, which is expected to propel the need for various strategies for effective treatment and to combat the increasing incidence of malignant tumors. Moreover, technological advancements in the market are expected to provide new opportunities for novel therapeutics. As a result, there is an increasing number of product approvals. For instance, in March 2022, European Medicine Agency recommended conditional marketing authorization for Carvykti (ciltacabtagene autoleucel) to be used for the treatment of subjects with relapsed and refractory multiple myeloma.

The market is positively driven by the lucrative support from the government and national cancer societies across the globe. There has been an increasing focus on increasing funds for research on cancer gene therapy. For instance, in December 2021, The Dutch platform called DARE-NL (in the Netherlands) has been awarded a USD 5.2 million grant from the KWF Dutch cancer society. The grant allows the DARE-NL to level up the availability of cell and gene therapy strategies accessible to the needy population.

The investment in new and complex technologies is relatively low for Asian manufacturers as they are more focused on less complex molecules that can be produced in bulk. Thus, the investment in high-yielding, low-cost technologies is an alternative for manufacturers in other developed regions such as Europe and North America to avoid competitive pressure.

Key players operating in the market are focusing on collaborations for the development of potent cancer gene therapy drugs. For instance, in August 2022, Gensaic signed a collaboration with Ovid Therapeutics for the development of up to three genetic medicines for central nervous system indications using its proprietary phage-derived particle gene therapy platform.

Cancer Gene Therapy Market Report Highlights:

  • The market is witnessing a key shift with the rise in gene level understanding of a cancer condition and rising need for gene induced immunotherapy and personalized medicine.
  • The gene induced immunotherapy segment held the largest share in 2024 due to increase in the advancement in gene induced immunotherapy research.
  • Biopharmaceutical companies held the largest market share in 2024 owing to rising demand for novel gene therapy and increasing number of FDA approvals for cancer gene therapy. Biopharmaceutical companies are anticipated to witness the fastest growth in the forecast period due to increasing research and development activities in the field.
  • North America dominated the market in 2024 due to the presence of key players and rising support from the government and National Cancer Institute to advance the research on oncology in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Indication
    • 1.2.2. Route of Administration
    • 1.2.3. Vector Type
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising prevalence of cancer
      • 3.2.1.2. Advancements in gene therapy technology
      • 3.2.1.3. Increasing adopton of personalized medicine
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High costs of treatment
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Cancer Gene Therapy Market: Indication Business Analysis

  • 4.1. Indication Segment Dashboard
  • 4.2. Global Cancer Gene Therapy Market Indication, Movement Analysis
  • 4.3. Global Cancer Gene Therapy Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 4.4. Large B-Cell Lymphoma
    • 4.4.1. Global Large B-Cell Lymphoma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Multiple Myeloma
    • 4.5.1. Global Multiple Myeloma Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Acute Lymphoblastic Leukemia (ALL)
    • 4.6.1. Global Acute Lymphoblastic Leukemia (ALL) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Melanoma (lesions)
    • 4.7.1. Global Melanoma (lesions) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cancer Gene Therapy Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Segment Dashboard
  • 5.2. Global Cancer Gene Therapy Market Route of Administration Movement Analysis
  • 5.3. Global Cancer Gene Therapy Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Intravenous
    • 5.4.1. Global Intravenous Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cancer Gene Therapy Market: VectorType Business Analysis

  • 6.1. Vector Type Segment Dashboard
  • 6.2. Global Cancer Gene Therapy Market Vector Type Movement Analysis
  • 6.3. Global Cancer Gene Therapy Market Size & Trend Analysis, by Vector Type, 2018 to 2030 (USD Million)
  • 6.4. Lentivirus
    • 6.4.1. Global Lentivirus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. RetroVirus & gamma RetroVirus
    • 6.5.1. Global RetroVirus & gamma RetroVirus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. AAV
    • 6.6.1. Global AAV Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Modified Herpes Simplex Virus
    • 6.7.1. Global Modified Herpes Simplex Virus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Adenovirus
    • 6.8.1. Global Adenovirus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Cancer Gene Therapy Market: Regional Estimates & Trend Analysis by Indication, Route of Administration, & Vector Type

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. North America Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. U.S. Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Canada Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Mexico Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. UK Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Germany Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Switzerland
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. France Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Japan Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. China Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. South Korea
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. South Korea Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Rest of the World
    • 7.6.1. Rest of the World Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2024
  • 8.4. Participant's Overview
    • 8.4.1. Amgen Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Novartis AG
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Gilead Sciences, Inc.
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. bluebird bio, Inc.
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Bristol-Myers Squibb Company
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Legend Biotech.
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Nanjing IASO Biotechnology
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. JW Therapeutics
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. CARsgen Therapeutics
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Krystal Biotech, Inc.
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives